Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00081861
Recruitment Status : Completed
First Posted : April 27, 2004
Results First Posted : August 26, 2009
Last Update Posted : April 5, 2012
Genentech, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
Phase II Study of Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma Drug: Avastin Drug: Rituximab Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Study Start Date : March 2004
Actual Primary Completion Date : September 2007
Actual Study Completion Date : September 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Avastin + Rituximab
Avastin 10 mg/kg given intravenously every 2 weeks for 4 doses, and Rituximab 375 mg/m^2 intravenously weekly for 8 doses.
Drug: Avastin
10 mg/kg given intravenously every 2 weeks for 4 doses.
Other Name: Bevacizumab

Drug: Rituximab
375 mg/m^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
Other Name: Rituxan

Primary Outcome Measures :
  1. Number of Participants With Response (Complete Response or Progressive Disease) [ Time Frame: After 8 weeks of therapy (4 doses of Avastin and 8 doses of Rituximab), ]
    Response criteria according to the International Working Group Recommendations for lymphoma where Complete Response (CR) defined as "complete disappearance" of clinically detectable disease and Progressive Disease defined by disease appearance by complete blood count (CBC), clinical and radiologic findings, and/or sizes of lymph nodes, spleen, and liver. Response measured from first documentation of response to first detection of progression.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Must have bi-dimensionally measurable, recurrent or chemotherapy - or Rituxan-refractory aggressive B-cell NHL (Diffuse large B-cell, transformed B-cell lymphoma, or Mantle cell lymphoma)
  • Patient who relapse after autologous (not allogeneic) stem cell transplantation are eligible.
  • Patients must have had prior Rituximab therapy, with response duration of at least 6 months to the last Rituximab-based therapy (single agent or in combination)
  • No anti-lymphoma therapy within the past 3 weeks, and no radiation therapy within 2 weeks.
  • Patients must not be eligible for treatment of a higher priority.
  • Must have a good performance status (<3 Zubrod, >/=60 Karnofsky).
  • Must have a good marrow reserve: ANC >/=1,000, Platelets >/=75,000.
  • Bilirubin </= 2mg/dl, SGOT or SGPT </= x 5 normal values.
  • Age > 18 (There is no information about the toxicity of Bevacizumab especially adverse effects on growth and development in pediatric patients).
  • Must sign a consent form.
  • Must have a life expectancy of > 12 weeks.

Exclusion Criteria:

  • HIV positive
  • History of serious cardiac disease such as myocardial infarction within 6 months of treatment, brady- or tachyarrhythmia, or clinically uncontrolled hypertension (blood pressure >160/110 mmHg).
  • Active infection or history of opportunistic infection.
  • Pregnant women or breast-feeding women.
  • Women of child-bearing age who are not practicing adequate contraception.
  • History of prior DVT or pulmonary embolus.
  • INR > 1.5
  • Serum creatinine > 2mg/dl, or clinically significant proteinuria (patients with >1+ proteinuria should have 24 hour urine collection and those with >2gm/day should be excluded).
  • Evidence of bleeding diathesis or coagulopathy.
  • History of other cancers within 5 years except for basal cell carcinoma of the skin.
  • Radiotherapy within 14 days of Day 0.
  • Current, recent (within 21 days of Day 0), or planned participation in an experimental drug study.
  • Hemoglobin <9gm/dl (may be transfused or receive epoetin alfa [e.g., Epogen]to maintain or exceed this level).
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.
  • Serious, non-healing wound, ulcer, or bone fracture.
  • History of CNS disease (including CNS involvement from primary cancer) or hemorrhagic or thrombotic stroke within the last 6 months.
  • History of hemoptysis requiring transfusion and/or hospitalization within the last 5 years.
  • Anatomic lesion that increase the risk of serious hemorrhage (e.g., invasion of a major vessel by tumor).
  • Current, ongoing treatment with full-dose warfarin or its equivalent.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0.
  • Fine needle aspirations, indwelling catheter placement, or core biopsy within 7 days prior to Day 0.
  • Anticipation of need for major surgical procedure during the course of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00081861

United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Genentech, Inc.
Principal Investigator: Barbara Pro, MD M.D. Anderson Cancer Center

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT00081861     History of Changes
Other Study ID Numbers: 2003-0520
First Posted: April 27, 2004    Key Record Dates
Results First Posted: August 26, 2009
Last Update Posted: April 5, 2012
Last Verified: April 2012

Keywords provided by M.D. Anderson Cancer Center:
Non-Hodgkin's Lymphoma
B-Cell Lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Immunologic Factors
Antirheumatic Agents